Mandate

Vinge advises Industrifonden in connection with its investment in InDex Pharmaceuticals

January 24, 2011

Vinge has advised Industrifonden in connection with its SEK 40 million investment in InDex Pharmaceuticals. InDex Pharmaceuticals develops Kappaproct, a drug developed for the treatment of severe inflammatory bowel disease. Further capital has also been raised from current shareholders, including SEB Venture Capital, which has invested an additional SEK 35 million. The financing will predominantly be used to conduct a clinical phase III trial using Kappaproct with the aim of obtaining market approval.

Vinge’s team consisted of, among others, project manager Johan Larsson and Petter Kjöllerström, who was responsible for the due diligence phase of the transaction. Johan Winnerblad was the responsible partner.

Related

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK in connection with the acquisition of Selatek

Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026

Vinge advises Right Side Group, a portfolio company of Alder, in connection with the acquisition of Brandkonsultbyrån i Sverige

Brandkonsultbyrån in Sweden is a technical consultant specialising in structural fire protection, evacuation safety and risk management. The acquisition strengthens the group’s position as a leading player in fire, risk and safety in the Nordic region.
April 17, 2026